Japan Tissue Engineering Co., Ltd. Logo

Japan Tissue Engineering Co., Ltd.

Develops, manufactures, and sells tissue-engineered medical products.

7774 | T

Overview

Corporate Details

ISIN(s):
JP3389610001
LEI:
Country:
Japan
Address:
蒲郡市三谷北通6丁目209番地の1

Description

Japan Tissue Engineering Co., Ltd. (J-TEC) is a company focused on the commercialization and industrialization of regenerative medicine. It develops, manufactures, and sells tissue-engineered medical products. The company operates through three primary business segments: the Regenerative Medicine Business, which provides its own therapeutic products such as autologous cultured cartilage and epidermis; the Custom Development & Manufacturing (CDMO) Business, offering contract services to support other developers in the field; and the LabCyte Business, which supplies cultured human tissue models for research and safety assessment purposes. J-TEC aims to establish regenerative medicine as a standard of care in healthcare.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-06-16 04:00
確認書
Japanese 8.4 KB
2022-06-16 03:58
有価証券報告書-第24期(令和3年4月1日-令和4年3月31日)
Japanese 914.0 KB
2022-02-14 06:18
四半期報告書-第24期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 162.5 KB
2021-11-12 04:09
四半期報告書-第24期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 181.6 KB
2021-08-12 07:05
四半期報告書-第24期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 157.8 KB
2021-06-25 07:05
確認書
Japanese 8.3 KB
2021-06-25 07:01
内部統制報告書-第23期(令和2年4月1日-令和3年3月31日)
Japanese 22.5 KB
2021-06-25 06:59
有価証券報告書-第23期(令和2年4月1日-令和3年3月31日)
Japanese 920.1 KB
2021-02-12 05:48
四半期報告書-第23期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese 164.5 KB
2021-02-01 07:00
意見表明報告書
Japanese 190.2 KB
2020-11-13 06:18
四半期報告書-第23期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 176.8 KB
2020-08-12 06:44
四半期報告書-第23期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 156.0 KB
2020-06-26 03:14
有価証券報告書-第22期(平成31年4月1日-令和2年3月31日)
Japanese 1.0 MB
2020-02-13 05:39
四半期報告書-第22期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese 146.2 KB
2019-11-13 06:46
四半期報告書-第22期第2四半期(2019/07/01-2019/09/30)
Japanese 170.6 KB

Automate Your Workflow. Get a real-time feed of all Japan Tissue Engineering Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Japan Tissue Engineering Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Japan Tissue Engineering Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.